Ciprofloxacin and cefazolin as a combination for empirical initial therapy of peritoneal dialysis-related peritonitis: Five-year follow-up

Peritoneal Dialysis International

Volumn 27, Issue 1, 2007, Pages 56-60

  Lima, Renata C S ^a   Barreira, André ^a   Cardoso, Fernando L ^a   Lima, Marcio H S ^a   Leite Jr , Maurilo ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cefazolin; Ciprofloxacin; Peritonitis

Indexed keywords

CEFAZOLIN; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APPLICATION SITE INFECTION; ARTICLE; AUTOMATION; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BRAZIL; CARIBBEAN ISLANDS; CATHETER INFECTION; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; EMPIRICAL RESEARCH; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FLUID; PERITONITIS; PRIORITY JOURNAL; TREATMENT RESPONSE; DRUG COMBINATION; MIDDLE AGED; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CEFAZOLIN; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONITIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947161435     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700113     Document Type: Article

References (30)

1. Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs 2002; 25:249-60.
2. Keane WF, Everett ED, Fine RN, Golper TA, Vass SI, Peterson PK. CAPD related peritonitis management and antibiotic therapy recommendations. Travenol Peritonitis Management Advisory Committee. Perit Dial Int 1987; 7:56-68.
3. Keane WF, Everett ED, Fine RN, Golper TA, Vas S, Peterson PK, et al. Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update. Perit Dial Int 1989; 9:247-56.
4. Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C, Kawaguchi Y, et al. Treatment recommendations of peritoneal dialysis related peritonitis: 1993 update. Perit Dial Int 1993; 13:14-28.
5. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA, et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996; 16:557-73.
6. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update [Published erratum appears in Perit Dial Int 2000; 20:828-9]. Perit Dial Int 2000; 20:396-411.
7. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-31.
8. Holley JL, Bernardini J, Johnston JR, Piraino B. Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program. Am J Kidney Dis 1990; 16: 142-6.
9. Boyle JF, Soumakis SA, Rendo A, Herrington JA, Gianarkis DG, Thurberg BE, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31: 1280-5.
10. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable van B class vancomycin resistance. J Clin Microbiol 1994; 32:1148-53.
11. Noble WC, Virani Z, Cree RCA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72:195-8.
12. Shemin D, Maaz D, St. Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999; 34:14-20.
13. Jacoby GA. Epidemiology of extended-spectrum beta-lactamases. Clin Infect Dis 1998; 27:81-3.
14. Lucet JC, Chevret S, Decre D, Vanjak D, Macrez A, Bedos JP, et al. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996; 22:430-6.
15. Kim DK, Yoo TH, Ryu DR, Xu ZG, Kim HJ, Choi KH, et al. Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. Perit Dial Int 2004; 24:424-32.
16. Perez FM, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337-41.
17. Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21:554-9.
18. Fleming LW, Moreland TA, Scott AC, Stuard WK, White LO. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1987; 19:493-503.
19. Goffin E, Herbiet L, Pouthier D, Pochet JM, Lafontaine JJ, Christophe JL, et al. Vancomycin and ciprofloxacin: systemic antibiotic administration for peritoneal dialysis-associated peritonitis. Perit Dial Int 2004; 24:433-9.
20. Janknegt R. CAPD peritonitis and fluoroquinolones: a review. Perit Dial Int 1991; 11:53-8.
21. Waite NM, Johnson MD, Webster NR, Fong IW. Poor response to oral ciprofloxacin in the treatment of peritonitis in patients on intermittent peritoneal dialysis. Perit Dial Int 1993; 13:50-4.
22. Cheng IK, Chan CY, Wong WT, Cheng SW, Ritchie CW, Cheung WC, et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13(Suppl 2): S351-4.
23. Trakarnvanich T, Thitiarchakul S, Kurathong P. Oral ciprofloxacin is ineffective in culture-negative peritonitis [Letter]. Perit Dial Int 2001; 21:199-200.
24. Ludlam HA, Barton I, White L, McMullin C, King A, Phillips I. Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother 1990; 25: 843-51.
25. Tapson JS, Orr KE, George JC, Stansfield E, Bint AJ, Ward MK. A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. J Antimicrob Chemother 1990; 26(Suppl F):63-71.
26. Dryden MS, Wing AJ, Phillips I. Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother 1991; 28:131-9.
27. Passadakis P, Oreopoulos D. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis. Adv Perit Dial 2001; 17:189-90.
28. Yeung SM, Walker SE, Tailor SA, Awdishu L, Tobe S, Yassa T. Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. Perit Dial Int 2004; 24:447-53.
29. Silva MM, Pecoits-Filho R, Rocha CS, Stinghen AE, Pachaly MA, Nascimento MM, et al. The recommendations from the International Society for Peritoneal Dialysis for peritonitis treatment: a single-center historical comparison. Adv Perit Dial 2004; 20:74-7.
30. Leung CB, Szeto CC, Chow KM, Kwan BC, Wang AY, Lui SF, et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis: a randomized controlled trial. Perit Dial Int 2004; 24: 440-6.